Journal Information
Vol. 98. Issue 1.
Pages 24-34 (January - February 2007)
Vol. 98. Issue 1.
Pages 24-34 (January - February 2007)
Original articles
Full text access
Expression of Galanin in Melanocytic Tumors
Estudio Sobre la Expresión de Galanina en Tumores Melanocitarios
Visits
6232
Y. Gilabertea,
Corresponding author
ygilaberte@salud.aragon.es

Correspondence: Sección de Dermatología. Hospital General San Jorge. Avda. Martínez de Velasco, 34. 22004 Huesca. Spain.
, J. Verab, C. Coscojuelaa, M.J. Rocab, C. Parradoc, S. Gonzálezd
a Sección de Dermatología, Hospital General San Jorge, Huesca, Spain
b Sección de Anatomía Patológica, Hospital General San Jorge, Huesca, Spain
c Departamento de Ciencias Morfológicas, Facultad de Medicina, Málaga, Spain
d Servicio de Dermatología, Memorial Sloan-Kettering Cancer Center, New York, USA
This item has received
Article information
Abstract
Introduction

Galanin is a neuropeptide with wide-ranging effects, especially within the endocrine and the nervous systems. Galanin and its receptors are present in human skin. Galanin is expressed in different neural, endocrine and neuroendocrine tumors and, on the other hand, several neuropeptides, especially α-MSH, seem to play a role in the pathogenesis of melanoma.

Objective

To investigate the expression of galanin in cutaneous melanomas and melanocytic nevi and correlate it with α-MSH expression and several prognostic factors for melanoma.

Patients and methods

We performed an observational, retrospective study of the immunohistochemical expression of galanin and α-MSH in samples of cutaneous melanomas diagnosed in the last 5 years in a tertiary care hospital. Different types of melanocytic nevi were also analyzed.

Results

A total of 130 pigmented lesions were studied: 38 primary cutaneous melanomas, 6 cutaneous metastases of melanoma and 86 melanocytic nevi. Immunostaining with galanin and α-MSH was significantly higher in melanomas than in melanocytic nevi (p<0.001), although spindle cell and blue nevi showed significant expression of α-MSH. More than 50% of nodular melanomas and 90% of superficial spreading melanomas were positive for galanin and ·-MSH, and the latter also showed the highest percentage of positive cells for galanin (mean 35,09±28,16) as well as for α-MSH (mean 67.64%±35,38). A positive correlation of 71% was found for immunostaining of both neuropeptides in melanomas. No significant correlation was observed between galanin expression and age, gender, location of the lesions, Breslow index, Clark level and mitotic index.

Conclusion

Our study shows the expression of galanin in cutaneous melanoma and its significant correlation with α-MSH immunostaining.

Key words:
galanin
α-MSH
melanoma
melanocytic nevus
Resumen
Introducción

La galanina es un neuropéptido que controla numerosas funciones en el sistema nervioso y endocrino y que está presente en la piel. Diferentes tumores neurales, endocrinos y neuroendocrinos expresan galanina y, por otro lado, varios neuropéptidos, especialmente la α-MSH, se han involucrado en la patogénesis del melanoma.

Objetivo

Estudiar la expresión de galanina en melanomas y nevi melanocíticos cutáneos, comparándola con la de α-?MSH, y relacionándola con variables clínicas e histológicas con valor pronóstico en el melanoma.

Métodos

Estudio observacional, retrospectivo de la expresión de galanina y α-MSH mediante inmunohistoquímica en una muestra significativa de secciones histológicas de los melanomas cutáneos diagnosticados en el hospital San Jorge de Huesca en los últimos 5 años, y un número similar de distintos tipos de nevi melanoctícos.

Resultados

Se estudiaron un total de 130 lesiones pigmentadas: 38 melanomas cutáneos primarios, 6 metástasis cutáneas de melanoma y 86 nevi melanocíticos. El inmunomarcaje con galanina y α-MSH fue significativamente mayor en melanomas que en nevi (p<0,001), aunque dentro de los nevi destacan la expresión de α-MSH en los azules y fusocelulares. Más del 50% de los melanomas nodulares y del 90% de los de extensión superificial fueron positivos para galanina y α-MSH, y además estos últimos fueron los que mostraron un mayor porcentaje de células positivas tanto para galanina (media= 35,09±28,16%) como para α-MSH (media=67,64%±35,38%), siendo la correlación entre ambos en melanomas del 71%. No se encontró asociación estadísticamente significativa entre la expresión de galanina y las variables edad, sexo, localización, índice de Breslow, nivel de Clark y proliferación celular.

Conclusión

Nuestro estudio demuestra la presencia de galanina en secciones histológicas de melanoma cutáneo, y esta inmunorreactividad se relaciona significativamente con la de α-MSH.

Palabras clave:
galanina
α-MSH
melanoma
nevus melanocítico
Full text is only aviable in PDF
References
[1.]
M. Steinhoff, S. Ständer, S. Seelinger, J.C. Ansel, M. Schemelz, T. Luger.
Modern aspects of cutaneous neurogenic inflammation.
Arch Dermatol, 139 (2003), pp. 1479-1488
[2.]
K. Seiffert, R.D. Granstein.
Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression.
Methods, 28 (2002), pp. 97-103
[3.]
M. Nagaham, Y. Funasaka, M.L. Fernández-Frez, A. Ohashi, A.K. Chakraborty, M. Ueda, et al.
Immunoreactivity of α-MSH, ACTH y b-endorphin in cutaneous malignant melanoma and benign melanocytic naevi.
Br J Dermatol, 138 (1998), pp. 981-985
[4.]
K.N. Charitopoulos, A.C. Lazaris, K. Aroni, N. Kavantzas, E. Nikilacopoulo, P. Davaris.
Immunodetection of gastrinreleasing peptide in malignant melanoma cells.
Melanoma Res, 10 (2000), pp. 395-400
[5.]
D.T. Lincoln, F. Sinowatz, S. Kolle, H. Takahashi, P. Pearsons, M. Waters.
Up-regulation of growth receptor immunoreactivity in human melanoma.
Anticancer Res, 19 (1999), pp. 1919-1931
[6.]
W.C. Scott, K. Wakamatsu, S. Ito, A.L. Kadekaro, N. Kobayashi, J. Groden, et al.
Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation.
J Cell Sci, 115 (2002), pp. 2349-2355
[7.]
N. Zhu, P.C. Eves, E. Katerinaki, M. Szabo, R. Morandini, G. Ghanem, et al.
Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone.
J Invest Dermatol, 119 (2002), pp. 1165-1171
[8.]
Mummies reveal medical secrets 1998. Available from: http://news6.thdo.bbc.co.uk/hi/english/sci/tech/newsid_
[9.]
M.E. Vrontakis.
Galanin: a biological active peptide.
Curr Drug Targets CNS Neurol Disord, 1 (2002), pp. 531-541
[10.]
P. Santha, F.K. Pierau, G. Jancso.
Inhibitory modulation of cutaneous vascular responses by endogenous galanin in the pigeon.
Neurosci Lett, 24 (1999), pp. 64-66
[11.]
B. Kofler, A. Berger, R. Santic, K. Moritz, D. Almer, C. Tuechler, et al.
Expression of neuropeptide galanin and galanin receptors in human skin.
J Invest Dermatol, 122 (2004), pp. 1050-1053
[12.]
A. Berger, R. Santic, C. Hauser-Kronberger, F.H. Shilling, P. Kogner, M. Ratschek, et al.
Galanin and galanin receptors in human cancers.
Neuropeptides, 39 (2005), pp. 353-355
[13.]
A. Berger, R. Lang, K. Moritz, R. Santic, A. Hermann, W. Sperl, et al.
Galanin receptor subtype GalR2 mediates apoptosis in SH-Sy5y neuroblastoma cells.
Endocrinology, 145 (2004), pp. 500-507
[14.]
M. El-Salhy, A. Starefeldt.
Direct effects of octreotide, galanin and serotonin on human colon cancer cells.
Oncol Rep, 10 (2003), pp. 1723-1728
[15.]
E. Habert-Ortoli, B. Amiranoff, I. Loquet, M. Laburthe, J.F. Mayaux.
Molecular cloning of a functional human galanin receptor.
Proc Natl Acad Sci USA, 91 (1994), pp. 9780-9783
[16.]
R.T. Miller, C. Estran.
Heat-induced epitope retrieval with a pressure cooker.
Appl Immunohistochem, 3 (1995), pp. 190-193
[17.]
T. Sano, M.E. Vrontakis, D. Kovacs, S.L. Asa, H.G. Freisen.
Galanin immunoreactivity in neuroendocrine tumors.
Arch Pathol Lab Med, 115 (1991), pp. 926-929
[18.]
Y. Perel, L. Amrein, E. Dobremez, J. Rivel, J.Y. Daniel, M. Landry.
Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status.
Br J Cancer, 86 (2002), pp. 117-122
[19.]
M. Nowicki, D. Ostalska-Novicka, B. Miskowiak.
Prognostic value of stage IV neuroblastoma metastatic immunophenotype in the bone marrow: preliminary report.
J Clin Pathol, 59 (2006), pp. 150-152
[20.]
A. Florén, T. Land, U. Langel.
Galanin receptor subtypes and ligand binding.
Neuropeptides, 34 (2000), pp. 331-337
[21.]
A. Berger, C. Tuechler, D. Almer, P. Kogner, M. Ratschek, R. Kerbl, et al.
Elevated expression of galanin receptors in childhood neuroblastic tumors.
Neuroendocrinology, 75 (2002), pp. 130-138
[22.]
E. Grenback, P. Bjellerup, E. Wallerman, L. Lundbland, A. Anggard, K. Ericson, et al.
Galanin in pituitary adenomas.
Regul Pept, 117 (2004), pp. 127-139
[23.]
P.C. Eves, S. MacNeil, J.W. Haycock.
a-Melanocyte stimulating hormone, inflammation and human melanoma.
[24.]
A.N. Crowson, C.M. Magro, M.C. Mihm.
Prognosticators of melanoma, the melanoma report, and the sentinel lymph node.
Modern Pathol, 19 (2006), pp. S71-S87
[25.]
J.I. Ru-Rong, X. Zhang, Q. Zhang, A. Dagerlind, S. Nilsson, Z. Wiesenfeld-Hallin, et al.
Central and peripheral expression of galanin in response to inflammation.
Neuroscience, 68 (1995), pp. 563-576

Juan de Azúa prize from the Spanish Academy of Dermatology and Venereology, 2006.

Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?